OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Revenue of OKYO Pharma Limited (OKYO)
Revenue in 2024 (TTM): $
According to OKYO Pharma Limited's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of OKYO Pharma Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $ | $-7,506 | $-15,746 | $-16,803 | $-16,825 |
| 2023 | $ | $-3,797 | $-13,183,403 | $-13,283,887 | $-13,271,685 |
| 2022 | $ | $-2,423 | $-6,215,235 | $-6,217,566 | $-5,431,045 |
| 2021 | $ | $-13,086 | $-3,353,095 | $-3,378,501 | $-3,353,507 |
| 2020 | $ | $-5,971 | $-1,512,880 | $-1,618,344 | $-1,542,149 |
| 2019 | $ | $-219 | $-4,539,207 | $-4,902,470 | $-4,902,470 |
| 2018 | $ | $ | $26.17 M | $-28,266,933 | $-28,266,933 |
| 2017 | $ | $ | $-363,269 | $-241,927 | $-241,927 |
| 2016 | $ | $ | $-1,124,877 | $-1,010,159 | $-820,171 |
| 2015 | $ | $ | $-1,751,357 | $-1,494,369 | $-8,255,049 |
| 2014 | $ | $ | $-4,670,954 | $-13,926,625 | $-13,926,625 |
| 2013 | $ | $ | $-4,695,626 | $-4,655,698 | $-4,655,698 |
| 2012 | $ | $ | $-5,088,764 | $-5,699,523 | $-4,804,369 |
| 2011 | $ | $ | $-1,703,413 | $-1,616,636 | $-1,616,636 |
| 2010 | $ | $ | $28.61 M | $12.67 M | $12.67 M |
| 2009 | $ | $ | $15.1 M | $14.33 M | $14.33 M |
| 2008 | $ | $ | $-3,165,059 | $-2,974,560 | $-2,974,560 |